Stocktwits on MSN

CMPS stock jumps 22% pre-market as Compass sets timeline for new phase 3 depression trial results

Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...

Why did Compass Pathways stock rocket higher today?

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.

Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass' psychedelic-based depression treatment scores second late-stage study win

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Compass Pathways Shares Rise After Psilocybin Therapy Achieves Trial Targets

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...